Inve India ▾

Wockhardt share price & results

Wockhardt· Healthcare

Results to
Jun 2026
Latest analysed call
Q4 FY26
Ownership as of
Sept 2026

Global research-driven pharma group discovering novel antibiotics and making branded generics and insulin biosimilars.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue929 ₹ crore+25.9% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin21.0 %+11.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit107 ₹ crore—Quarterly, as filedQuarter to Jun 2026Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.
Return on equity8.58 %+7.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin2.25 %+14.8 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)18.37 %+4.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

1 of 5 judged targets kept · 10 open · verdicts reflect calls analysed to Q4 FY26.

Wockhardt management guidance track record on Inve: 15 targets tracked across analysed earnings calls (1 achieved, 4 missed, 10 open).

TargetOriginal wordingSaidLatest callVerdict
PBT Positive Statusturn completely PBT positive in 2 years from nowQ3 FY23Q4 FY26:Company reported PBT of INR 238 crores for FY26. This confirms the target for FY25 was not met.
Call transcript, Q4 FY26 · 4 Jun 2026		Missed
Biosimilar Capacitydouble our capacities over the next 24 months and put up new facility
Call transcript, Q4 FY25 · 5 Jun 2025		Q4 FY25Q4 FY26:Timeline accelerated: 'we will double our capacity in the next 12 to 15 months.'
Call transcript, Q4 FY26 · 4 Jun 2026		Revised Up
Biosimilar Business Sizeexpect to double the business in the next 3 years
Call transcript, Q4 FY25 · 5 Jun 2025		Q4 FY25Q4 FY26:Management reiterated the goal to double the business in the next 24-36 months. The business grew 27% in FY26, showing strong progress.
Call transcript, Q4 FY26 · 4 Jun 2026		On Track

Source: Inve Guidance Tracker for Wockhardt · to Q4 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

4 of Wockhardt's 15 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 12 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,809.6 +0.44% · +₹7.9

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance +35.8% 1Y

₹1.5k₹2.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q4 FY26 — 4 Jun 2026

1Y: ₹1,332.4 on 24 Oct 2025 → ₹1,809.6. High ₹2,329.7 (23 Sept 2026), low ₹1,100.3 (23 Mar 2026).

Previous close
₹1,801.7
Market cap
₹30.6k Cr
52-week range
₹1,100.3 – ₹2,329.7
One year
+39.80%
Price to earnings (TTM to Jun 2026)
76.73×
Return on equity (TTM to Jun 2026)
8.58%

Overview

Symbol
NSE:WOCKPHARMA
Exchange
NSE
Currency
INR

What Wockhardt does

Based on the company's own presentations, annual report and earnings calls.

Wockhardt is a global research-led healthcare company operating across three lines: novel antibiotic discovery targeting antimicrobial resistance, an integrated diabetes-biosimilars franchise spanning human insulin and insulin analogues, and branded/specialty pharmaceuticals sold in India and international markets including the UK, Ireland and emerging markets. It earns by manufacturing and selling branded generic drugs and specialty injectables through its own facilities and country subsidiaries (including UK-based Pinewood), and by licensing/commercializing its novel antibiotic pipeline, most notably Zaynich, which became the first Indian-discovered drug to receive US FDA approval.

Segments

  • Novel Antibiotics
  • Biotechnology
  • Pharmaceuticals
Manufacturing facilities
11, across the globe
R&D centers
2 (India and UK)
Biosimilar products commercialized
2 (Recombinant Human Insulin, Glargine)
Biosimilar pipeline assets (R&D through Phase III)
5 (Aspart R, Aspart 30/70, Degludec, Degludec+Aspart, Semaglutide)
Emerging markets with biosimilars registered & actively supplied
30+ markets
UK subsidiary market position
Pinewood holds market leadership in Methadone, Pinamox, Codeine, Flucillin and Cortopin
Headquarters Wockhardt Towers, Bandra-Kurla Complex, Bandra (East), Mumbai 400051 Company website

How the price took the results

close before → close after

Q4 FY26
−0.0%
4 Jun

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Wockhardt

Free account: one company. Everything above stays public.

Write why you follow Wockhardt and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Wockhardt

Guides on how to read this kind of business and the numbers that matter.